Genetic association of interleukin-6 polymorphism (-174 G/C) with chronic liver diseases and hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 19, Issue 16, 2013, Pages 2449-2455

  Giannitrapani, Lydia ^a   Soresi, Maurizio ^a   Balasus, Daniele ^a   Licata, Anna ^a   Montalto, Giuseppe ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Chronic hepatitis; Hepatocellular carcinoma; Interleukin 6; Liver cirrhosis; Single nucleotide polymorphisms

Indexed keywords

ALANINE AMINOTRANSFERASE; GLYCOPROTEIN GP 130; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; INTERLEUKIN 8; STAT3 PROTEIN;

ALLELE; ARTICLE; AUTOIMMUNE LIVER DISEASE; CHRONIC LIVER DISEASE; DNA POLYMORPHISM; GENETIC ASSOCIATION; GENOTYPE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84877250629     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i16.2449     Document Type: Article

References (67)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-567 [PMID: 16122679 DOI: 10.1016/S1473-3099(05)70216-4]
2. Averhoff FM, Glass N, Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin Infect Dis 2012; 55 Suppl 1: S10-S15 [PMID: 22715208 DOI: 10.1093/cid/cis361]
3. Spradling PR, Rupp L, Moorman AC, Lu M, Teshale EH, Gordon SC, Nakasato C, Boscarino JA, Henkle EM, Nerenz DR, Denniston MM, Holmberg SD. Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence. Clin Infect Dis 2012; 55: 1047-1055 [PMID: 22875876 DOI: 10.1093/ cid/cis616]
4. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of agespecific HBsAg seroprevalence and endemicity. Vaccine 2012; 30: 2212-2219 [PMID: 22273662 DOI: 10.1016/j.vaccine. 2011.12.116]
5. McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis 2011; 15: 223-243, vii-x [PMID: 21689610 DOI: 10.1016/ j.cld.2011.03.006]
6. Alison MR, Nicholson LJ, Lin WR. Chronic inflammation and hepatocellular carcinoma. Recent Results Cancer Res 2011; 185: 135-148 [PMID: 21822824 DOI: 10.1007/978-3-642-03503-6_8]
7. Bowcock AM, Kidd JR, Lathrop GM, Daneshvar L, May LT, Ray A, Sehgal PB, Kidd KK, Cavalli-Sforza LL. The human "interferon-beta 2/hepatocyte stimulating factor/interleu-kin-6" gene: DNA polymorphism studies and localization to chromosome 7p21. Genomics 1988; 3: 8-16 [PMID: 2906047 DOI: 10.1016/0888-7543(88)90152-8]
8. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102: 1369-1376 [PMID: 9769329 DOI: 10.1172/JCI2629]
9. Olomolaiye O, Wood NA, Bidwell JL. A novel polymorphism in the human IL-6 promoter. Eur J Immunogenet 1998; 25: 267 [DOI: 10.1046/j.1365-2370.1998.00077.x]
10. Cox ED, Hoffmann SC, DiMercurio BS, Wesley RA, Harlan DM, Kirk AD, Blair PJ. Cytokine polymorphic analyses indicate ethnic differences in the allelic distribution of interleukin-2 and interleukin-6. Transplantation 2001; 72: 720-726 [PMID: 11544437 DOI: 10.1097/00007890-200108270-00027]
11. Meenagh A, Williams F, Ross OA, Patterson C, Gorodezky C, Hammond M, Leheny WA, Middleton D. Frequency of cytokine polymorphisms in populations from western Europe, Africa, Asia, the Middle East and South America. Hum Immunol 2002; 63: 1055-1061 [PMID: 12392859 DOI: 10.1016/ S0198-8859(02)00440-8]
12. Spanakis NE, Garinis GA, Alexopoulos EC, Patrinos GP, Menounos PG, Sklavounou A, Manolis EN, Gorgoulis VG, Valis D. Cytokine serum levels in patients with chronic HCV infection. J Clin Lab Anal 2002; 16: 40-46 [PMID: 11835530 DOI: 10.1002/jcla.2060]
13. Martinez F, Abril ER, Earnest DL, Watson RR. Ethanol and cytokine secretion. Alcohol 1992; 9: 455-458 [PMID: 1472299 DOI: 10.1016/S0741-8329(00)00076-8]
14. Soresi M, Giannitrapani L, D'Antona F, Florena AM, La Spada E, Terranova A, Cervello M, D'Alessandro N, Montalto G. Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol 2006; 12: 2563-2568 [PMID: 16688802]
15. Giannitrapani L, Soresi M, Giacalone A, Campagna ME, Marasà M, Cervello M, Marasà S, Montalto G. IL-6-174G/C polymorphism and IL-6 serum levels in patients with liver cirrhosis and hepatocellular carcinoma. OMICS 2011; 15: 183-186 [PMID: 21329460 DOI: 10.1089/omi.2010.0093]
16. Tacke RS, Tosello-Trampont A, Nguyen V, Mullins DW, Hahn YS. Extracellular hepatitis C virus core protein activates STAT3 in human monocytes/macrophages/dendritic cells via an IL-6 autocrine pathway. J Biol Chem 2011; 286: 10847-10855 [PMID: 21282107 DOI: 10.1074/jbc.M110.217653]
17. Kao JT, Lai HC, Tsai SM, Lin PC, Chuang PH, Yu CJ, Cheng KS, Su WP, Hsu PN, Peng CY, Wu YY. Rather than interleukin-27, interleukin-6 expresses positive correlation with liver severity in naïve hepatitis B infection patients. Liver Int 2012; 32: 928-936 [PMID: 22230324 DOI: 10.1111/j.1478-3231. 2011.02742.x]
18. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003; 374: 1-20 [PMID: 12773095 DOI: 10.1042/BJ20030407]
19. Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond) 2012; 122: 143-159 [PMID: 22029668 DOI: 10.1042/CS20110340]
20. Barrett S, Collins M, Kenny C, Ryan E, Keane CO, Crowe J. Polymorphisms in tumour necrosis factor-alpha, transforming growth factor-beta, interleukin-10, interleukin-6, interferon-gamma, and outcome of hepatitis C virus infection. J Med Virol 2003; 71: 212-218 [PMID: 12938195]
21. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401 [PMID: 19684573 DOI: 10.1038/nature08309]
22. Yee LJ, Im K, Borg B, Yang H, Liang TJ. Interleukin-6 haplotypes and the response to therapy of chronic hepatitis C virus infection. Genes Immun 2009; 10: 365-372 [PMID: 19387461 DOI: 10.1038/gene.2009.26]
23. Nattermann J, Vogel M, Berg T, Danta M, Axel B, Mayr C, Bruno R, Tural C, Klausen G, Clotet B, Lutz T, Grünhage F, Rausch M, Nischalke HD, Schewe K, Bienek B, Haerter G, Sauerbruch T, Rockstroh JK, Spengler U. Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients. Hepatology 2007; 46: 1016-1025 [PMID: 17668881]
24. Alberti A, Benvegnù L, Boccato S, Ferrari A, Sebastiani G. Natural history of initially mild chronic hepatitis C. Dig Liver Dis 2004; 36: 646-654 [PMID: 15506661 DOI: 10.1016/ j.dld.2004.06.011]
25. Falleti E, Fabris C, Vandelli C, Colletta C, Cussigh A, Smirne C, Fontanini E, Cmet S, Minisini R, Bitetto D, Toniutto P, Pirisi M. Genetic polymorphisms of interleukin-6 modulate fibrosis progression in mild chronic hepatitis C. Hum Immunol 2010; 71: 999-1004 [PMID: 20655350 DOI: 10.1016/ j.humimm.2010.06.006]
26. Park BL, Lee HS, Kim YJ, Kim JY, Jung JH, Kim LH, Shin HD. Association between interleukin 6 promoter variants and chronic hepatitis B progression. Exp Mol Med 2003; 35: 76-82 [PMID: 12754410]
27. Ribeiro CS, Visentainer JE, Moliterno RA. Association of cytokine genetic polymorphism with hepatitis B infection evolution in adult patients. Mem Inst Oswaldo Cruz 2007; 102: 435-440 [PMID: 17612762 DOI: 10.1590/S0074-02762007005000043]
28. Migita K, Miyazoe S, Maeda Y, Daikoku M, Abiru S, Ueki T, Yano K, Nagaoka S, Matsumoto T, Nakao K, Hamasaki K, Yatsuhashi H, Ishibashi H, Eguchi K. Cytokine gene polymorphisms in Japanese patients with hepatitis B virus infection--association between TGF-beta1 polymorphisms and hepatocellular carcinoma. J Hepatol 2005; 42: 505-510 [PMID: 15763337 DOI: 10.1016/j.jhep.2004.11.026]
29. McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2004; 8: 521-533, viii [PMID: 15331061 DOI: 10.1016/ j.cld.2004.04.004]
30. Wilfred de Alwis NM, Day CP. Genes and nonalcoholic fatty liver disease. Curr Diab Rep 2008; 8: 156-163 [PMID: 18445359 DOI: 10.1007/s11892-008-0027-9]
31. Younossi ZM, Baranova A, Ziegler K, Del Giacco L, Schlauch K, Born TL, Elariny H, Gorreta F, VanMeter A, Younoszai A, Ong JP, Goodman Z, Chandhoke V. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology 2005; 42: 665-674 [PMID: 16116632 DOI: 10.1002/hep.20838]
32. Tilg H. The role of cytokines in non-alcoholic fatty liver disease. Dig Dis 2010; 28: 179-185 [PMID: 20460908 DOI: 10.1159/000282083]
33. Carulli L, Canedi I, Rondinella S, Lombardini S, Ganazzi D, Fargion S, De Palma M, Lonardo A, Ricchi M, Bertolotti M, Carulli N, Loria P. Genetic polymorphisms in non-alcoholic fatty liver disease: interleukin-6-174G/C polymorphism is associated with non-alcoholic steatohepatitis. Dig Liver Dis 2009; 41: 823-828 [PMID: 19403348 DOI: 10.1016/j.dld.2009.03.005]
34. Fernández-Real JM, Broch M, Vendrell J, Richart C, Ricart W. Interleukin-6 gene polymorphism and lipid abnormalities in healthy subjects. J Clin Endocrinol Metab 2000; 85: 1334-1339 [PMID: 10720087 DOI: 10.1210/jc.85.3.1334]
35. Hamid YH, Rose CS, Urhammer SA, Glümer C, Nolsøe R, Kristiansen OP, Mandrup-Poulsen T, Borch-Johnsen K, Jorgensen T, Hansen T, Pedersen O. Variations of the interleukin-6 promoter are associated with features of the metabolic syndrome in Caucasian Danes. Diabetologia 2005; 48: 251-260 [PMID: 15645209 DOI: 10.1007/s00125-004-1623-0]
36. Vozarova B, Fernández-Real JM, Knowler WC, Gallart L, Hanson RL, Gruber JD, Ricart W, Vendrell J, Richart C, Tataranni PA, Wolford JK. The interleukin-6 (-174) G/C promoter polymorphism is associated with type-2 diabetes mellitus in Native Americans and Caucasians. Hum Genet 2003; 112: 409-413 [PMID: 12589429 DOI: 10.1007/s00439-003-0912-x]
37. Cardellini M, Perego L, D'Adamo M, Marini MA, Procopio C, Hribal ML, Andreozzi F, Frontoni S, Giacomelli M, Paganelli M, Pontiroli AE, Lauro R, Folli F, Sesti G. C-174G polymorphism in the promoter of the interleukin-6 gene is associated with insulin resistance. Diabetes Care 2005; 28: 2007-2012 [PMID: 16043746 DOI: 10.2337/diacare.28.8.2007]
38. Illig T, Bongardt F, Schöpfer A, Müller-Scholze S, Rathmann W, Koenig W, Thorand B, Vollmert C, Holle R, Kolb H, Herder C. Significant association of the interleukin-6 gene polymorphisms C-174G and A-598G with type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 5053-5058 [PMID: 15472205 DOI: 10.1210/jc.2004-0355]
39. Chang YH, Huang CN, Shiau MY. The C-174G promoter polymorphism of the interleukin-6 (IL-6) gene that affects insulin sensitivity in Caucasians is not involved in the pathogenesis of Taiwanese type 2 diabetes mellitus. Eur Cytokine Netw 2004; 15: 117-119 [PMID: 15319170]
40. Miller AM, Wang H, Bertola A, Park O, Horiguchi N, Ki SH, Yin S, Lafdil F, Gao B. Inflammation-associated interleukin-6/signal transducer and activator of transcription 3 activation ameliorates alcoholic and nonalcoholic fatty liver diseases in interleukin-10-deficient mice. Hepatology 2011; 54: 846-856 [PMID: 21725996 DOI: 10.1002/hep.24517]
41. Reed T, Page WF, Viken RJ, Christian JC. Genetic predisposition to organ-specific endpoints of alcoholism. Alcohol Clin Exp Res 1996; 20: 1528-1533 [PMID: 8986199 DOI: 10.1111/ j.1530-0277.1996.tb01695.x]
42. Stickel F, Osterreicher CH. The role of genetic polymorphisms in alcoholic liver disease. Alcohol Alcohol 2006; 41: 209-224 [PMID: 16492723 DOI: 10.1093/alcalc/agl011]
43. Crews FT, Bechara R, Brown LA, Guidot DM, Mandrekar P, Oak S, Qin L, Szabo G, Wheeler M, Zou J. Cytokines and alcohol. Alcohol Clin Exp Res 2006; 30: 720-730 [PMID: 16573591 DOI: 10.1111/j.1530-0277.2006.00084.x]
44. Laso FJ, Vaquero JM, Almeida J, Marcos M, Orfao A. Chronic alcohol consumption is associated with changes in the distribution, immunophenotype, and the inflammatory cytokine secretion profile of circulating dendritic cells. Alcohol Clin Exp Res 2007; 31: 846-854 [PMID: 17386065 DOI: 10.1111/ j.1530-0277.2010.01160.x]
45. Laso FJ, Vaquero JM, Almeida J, Marcos M, Orfao A. Production of inflammatory cytokines by peripheral blood monocytes in chronic alcoholism: relationship with ethanol intake and liver disease. Cytometry B Clin Cytom 2007; 72: 408-415 [PMID: 17266151 DOI: 10.1002/cyto.b.20169]
46. McClain CJ, Song Z, Barve SS, Hill DB, Deaciuc I. Recent advances in alcoholic liver disease. IV. Dysregulated cytokine metabolism in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 2004; 287: G497-G502 [PMID: 15331349 DOI: 10.1152/ajpgi.00171.2004]
47. Nanji AA, Jokelainen K, Rahemtulla A, Miao L, Fogt F, Matsumoto H, Tahan SR, Su GL. Activation of nuclear factor kappa B and cytokine imbalance in experimental alcoholic liver disease in the rat. Hepatology 1999; 30: 934-943 [PMID: 10498645 DOI: 10.1002/hep.510300402]
48. Marcos M, Pastor I, González-Sarmiento R, Laso FJ. Common polymorphisms in interleukin genes (IL4, IL6, IL8 and IL12) are not associated with alcoholic liver disease or alcoholism in Spanish men. Cytokine 2009; 45: 158-161 [PMID: 19185507 DOI: 10.1016/j.cyto.2008.11.003]
49. Czaja AJ, Strettell MD, Thomson LJ, Santrach PJ, Moore SB, Donaldson PT, Williams R. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology 1997; 25: 317-323 [PMID: 9021941 DOI: 10.1002/hep.510250211]
50. Pando M, Larriba J, Fernandez GC, Fainboim H, Ciocca M, Ramonet M, Badia I, Daruich J, Findor J, Tanno H, Cañero-Velasco C, Fainboim L. Pediatric and adult forms of type I autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. Hepatology 1999; 30: 1374-1380 [PMID: 10573514 DOI: 10.1002/hep.510300611]
51. Jones DE, Watt FE, Metcalf JV, Bassendine MF, James OF. Familial primary biliary cirrhosis reassessed: a geographically-based population study. J Hepatol 1999; 30: 402-407 [PMID: 10190721 DOI: 10.1016/S0168-8278(99)80097-X]
52. Mella JG, Roschmann E, Maier KP, Volk BA. Association of primary biliary cirrhosis with the allele HLA-DPB1*0301 in a German population. Hepatology 1995; 21: 398-402 [PMID: 7843712]
53. Fan LY, Tu XQ, Zhu Y, Pfeiffer T, Feltens R, Stoecker W, Zhong RQ. Genetic association of cytokines polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in the Chinese. World J Gastroenterol 2005; 11: 2768-2772 [PMID: 15884119]
54. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-545 [PMID: 11229684 DOI: 10.1016/S0140-6736(00)04046-0]
55. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-867 [PMID: 12490959 DOI: 10.1038/nature01322]
56. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441: 431-436 [PMID: 16724054 DOI: 10.1038/nature04870]
57. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436-444 [PMID: 18650914 DOI: 10.1038/nature07205]
58. Kuper H, Adami HO, Trichopoulos D. Infections as a major preventable cause of human cancer. J Intern Med 2000; 248: 171-183 [PMID: 10971784 DOI: 10.1046/j.1365-2796. 2000.00742.x]
59. Farinati F, Cardin R, Cassaro M, Bortolami M, Nitti D, Tieppo C, Zaninotto G, Rugge M. Helicobacter pylori, inflammation, oxidative damage and gastric cancer: a morphological, biological and molecular pathway. Eur J Cancer Prev 2008; 17: 195-200 [PMID: 18414189 DOI: 10.1097/CEJ.0b013e3282f0bff5]
60. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576 [PMID: 17570226 DOI: 10.1053/j.gastro. 2007.04.061]
61. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006; 6: 674-687 [PMID: 16929323 DOI: 10.1038/nrc1934]
62. Luedde T, Schwabe RF. NF-κB in the liver--linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2011; 8: 108-118 [PMID: 21293511 DOI: 10.1038/nrgastro.2010.213]
63. He G, Karin M. NF-κB and STAT3key players in liver inflammation and cancer. Cell Res 2011; 21: 159-168 [PMID: 21187858 DOI: 10.1038/cr.2010.183]
64. Johnson C, Han Y, Hughart N, McCarra J, Alpini G, Meng F. Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer. Transl Gastrointest Cancer 2012; 1: 58-70 [PMID: 22724089 DOI: 10.3978/j.issn.2224-4778.2011.11.02]
65. Nieters A, Yuan JM, Sun CL, Zhang ZQ, Stoehlmacher J,Govindarajan S, Yu MC. Effect of cytokine genotypes on the hepatitis B virus-hepatocellular carcinoma association. Cancer 2005; 103: 740-748 [PMID: 15643599 DOI: 10.1002/cncr.20842]
66. Ognjanovic S, Yuan JM, Chaptman AK, Fan Y, Yu MC. Genetic polymorphisms in the cytokine genes and risk of hepatocellular carcinoma in low-risk non-Asians of USA. Carcinogenesis 2009; 30: 758-762 [PMID: 19126646 DOI: 10.1093/ carcin/bgn286]
67. Falleti E, Fabris C, Toniutto P, Fontanini E, Cussigh A, Bitetto D, Fumolo E, Fornasiere E, Bragagnini W, Pinato DJ, Minisini R, Pirisi M. Interleukin-6 polymorphisms and gender: relationship with the occurrence of hepatocellular carcinoma in patients with end-stage liver disease. Oncology 2009; 77: 304-313 [PMID: 19940521 DOI: 10.1159/000260057]